Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Langenbeck's Archives of Surgery
Erschienen in: Langenbeck's Archives of Surgery 5/2018

12.07.2018 | ORIGINAL ARTICLE

Renal cell cancer after kidney transplantation

verfasst von: Dennis Kleine-Döpke, Matthias Oelke, Anke Schwarz, Ysabell Schwager, Frank Lehner, Jürgen Klempnauer, Harald Schrem

Erschienen in: Langenbeck's Archives of Surgery | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study aims to identify modifiable risk factors for de novo renal cell carcinoma (RCC) after kidney transplantation in a matched-pair approach matching for unmodifiable factors.

Patients and methods

One thousand six hundred fifty-five adults who underwent kidney transplantation in the period 1 January 2000 to 31 December 2012 were analyzed. Patients with RCC after kidney transplantation were matched in a 1:2 ratio with those without RCC using the indication for transplantation, age at transplantation (± 10 years), recipient sex (male/female), number of received transplants, living organ donor transplantation (yes/no), and time of follow-up in days as matching criteria. The paired t test was used to compare continuous variables and the Cochran-Mantel-Haenszel test for categorical variables. Multivariable conditional logistic regression modeling was used to identify independent risk factors for RCC.

Results

In matched-pair analysis, a total number of 26 incident cases with RCC after kidney transplantation could be matched. Post-transplant RCC was significantly associated with longer durations of pre-transplant hemodialysis (p = 0.007) and post-transplant immunosuppression with cyclosporine (p = 0.029) and/or mycophenolate mofetil (p = 0.020) and with larger proportions of post-transplant time on mycophenolate mofetil (p = 0.046) and/or prednisolone medication (p = 0.042). Multivariable conditional logistic regression modeling revealed a significant risk increasing multiplicative factor interaction between the duration of pre-transplant dialysis (years) and the time of prednisolone usage (percent/100). Cyclosporine A usage and mycophenolate mofetil usage were also revealed as independent, significant risk factors for RCC development.

Conclusions

Longer pre-transplant dialysis, cyclosporine-based protocols and/or intensified immunosuppression with additional mycophenolate mofetil, and larger proportions of time of prednisolone treatment during follow-up increase de novo RCC risk.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Kaatsch P, Spix C, Hentschel S et al (2013) Krebs in Deutschland 2009/2010. 9. Ausgabe. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg). Ruksaldruck, Berlin, ISBN 978-3-89606-221-5
2.
3.
4.
5.
6.
Navai N, Wood CG (2012) Environmental and modifiable risk factors in renal cell carcinoma. Urol Oncol 30(2):220–224CrossRefPubMed
7.
Macleod LC, Hotaling JM, Wright JL, Davenport MT, Gore JL, Harper J, White E (2013) Risk factors for renal cell carcinoma in the VITAL study. J Urol 190(5):1657–1661CrossRefPubMedPubMedCentral
8.
Chow WH, Gridley G, Fraumeni JF Jr, Järvholm B (2000) Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med 343(18):1305–1311CrossRefPubMed
9.
10.
Wang G, Hou J, Ma L, Xie J, Yin J, Xu D, Chang W, Tan X, Su T, Zhang H, Cao G (2012) Risk factor for clear cell renal cell carcinoma in Chinese population: a case-control study. Cancer Epidemiol 36(2):177–182CrossRefPubMed
11.
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371(9612):569–578CrossRefPubMed
12.
Stewart JH, Buccianti G, Agodoa L, Gellert R, McCredie MR, Lowenfels AB, Disney AP, Wolfe RA, Boyle P, Maisonneuve P (2003) Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol 14(1):197–207CrossRefPubMed
13.
Woldu SL, Weinberg AC, RoyChoudhury A, Chase H, Kalloo SD, McKiernan JM, DeCastro GJ (2014) Renal insufficiency is associated with an increased risk of papillary renal cell carcinoma histology. Int Urol Nephrol 46(11):2127–2132CrossRefPubMed
14.
Otunctemur A, Ozbek E, Sahin S, Dursun M, Besiroglu H, Koklu I, Erkoc M, Danis E, Bozkurt M, Gurbuz A (2014) Diabetes mellitus as a risk factor for high grade renal cell carcinoma. Asian Pac J Cancer Prev 15(9):3993–3996CrossRefPubMed
15.
Schrem H, Kurok M, Kaltenborn A, Vogel A, Walter U, Zachau L, Manns MP, Klempnauer J, Kleine M (2013) Incidence and long-term risk of de novo malignancies after liver transplantation with implications for prevention and detection. Liver Transpl 19(11):1252–1261CrossRefPubMed
16.
Leveridge M, Musquera M, Evans A, Cardella C, Pei Y, Jewett M, Robinette M, Finelli A (2011) Renal cell carcinoma in the native and allograft kidneys of renal transplant recipients. J Urol 186(1):219–223CrossRefPubMed
17.
Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM (2007) Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370(9581):59–67CrossRefPubMed
18.
Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA, Jiang Y, Mao Y (2007) Cancer incidence among Canadian kidney transplant recipients. Am J Transplant 7(4):941–948CrossRefPubMed
19.
Moudouni SM, Lakmichi A, Tligui M, Rafii A, Tchala K, Haab F, Gattegno B, Thibault P, Doublet JD (2006) Renal cell carcinoma of native kidney in renal transplant recipients. BJU Int 98(2):298–302CrossRefPubMed
20.
Kasiske BL, Snyder JJ, Gilbertson DT, Wang C (2004) Cancer after kidney transplantation in the United States. Am J Transplant 4(6):905–913CrossRefPubMed
21.
Adami J, Gäbel H, Lindelöf B, Ekström K, Rydh B, Glimelius B, Ekbom A, Adami HO, Granath F (2003) Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 89(7):1221–1227CrossRefPubMedPubMedCentral
22.
23.
Collett D, Mumford L, Banner NR, Neuberger J, Watson C (2010) Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant 10(8):1889–1896CrossRefPubMed
24.
25.
Engels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL, Israni AK, Snyder JJ, Wolfe RA, Goodrich NP, Bayakly AR, Clarke CA, Copeland G, Finch JL, Fleissner ML, Goodman MT, Kahn A, Koch L, Lynch CF, Madeleine MM, Pawlish K, Rao C, Williams MA, Castenson D, Curry M, Parsons R, Fant G, Lin M (2011) Spectrum of cancer risk among US solid organ transplant recipients. JAMA 306(17):1891–1901CrossRefPubMedPubMedCentral
26.
Tsivian M, Caso JR, Kimura M, Polascik TJ (2013) Renal tumors in solid organ recipients: clinical and pathologic features. Urol Oncol 31(2):255–258CrossRefPubMed
27.
Végsö G, Toronyi E, Hajdu M, Piros L, Görög D, Deák PA, Doros A, Péter A, Langer RM (2011) Renal cell carcinoma of the native kidney: a frequent tumor after kidney transplantation with favorable prognosis in case of early diagnosis. Transplant Proc 43(4):1261–1263CrossRefPubMed
28.
Cheung CY, Lam MF, Lee KC, Chan GS, Chan KW, Chau KF, Li CS, Chan TM, Lai KN (2011) Renal cell carcinoma of native kidney in Chinese renal transplant recipients: a report of 12 cases and a review of the literature. Int Urol Nephrol 43(3):675–680CrossRefPubMedPubMedCentral
29.
Gigante M, Neuzillet Y, Patard JJ, Tillou X, Thuret R, Branchereau J, Timsit MO, Terrier N, Boutin JM, Sallusto F, Karam G, Barrou B, Chevallier D, Mazzola CR, Delaporte V, Doeffler A, Kleinclauss F, Badet L, the members of the Comité de Cancerologie de l'Association Française d'Urologie (CCAFU) and Comité de Transplantation de l'Association Française d'Urologie (CTAFU) (2012) Renal cell carcinoma (RCC) arising in native kidneys of dialyzed and transplant patients: are they different entities? BJU Int 110(11 Pt B):E570–E573CrossRefPubMed
30.
Schwarz A, Vatandaslar S, Merkel S, Haller H (2007) Renal cell carcinoma in transplant recipients with acquired cystic kidney disease. Clin J Am Soc Nephrol 2:750–756CrossRefPubMed
31.
Karczewski M, Rzymski P, Karczewski J (2012) De novo renal cell carcinoma of native kidneys in renal transplant recipients: a single-center experience. Exp Clin Transplant 10(4):310–313CrossRefPubMed
32.
Denton MD, Magee CC, Ovuworie C, Mauiyyedi S, Pascual M, Colvin RB, Cosimi AB, Tolkoff-Rubin N (2002) Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a pathologic analysis. Kidney Int 61(6):2201–2209CrossRefPubMed
33.
Hofmann JN, Schwartz K, Chow WH, Ruterbusch JJ, Shuch BM, Karami S, Rothman N, Wacholder S, Graubard BI, Colt JS, Purdue MP (2013) The association between chronic renal failure and renal cell carcinoma may differ between black and white Americans. Cancer Causes Control 24(1):167–174CrossRefPubMed
34.
Hurst FP, Jindal RM, Graham LJ, Falta EM, Elster EA, Stackhouse GB, Agodoa LY, Lentine KL, Salifu MO, Abbott KC (2010) Incidence, predictors, costs, and outcome of renal cell carcinoma after kidney transplantation: USRDS experience. Transplantation 90(8):898–904PubMed
35.
Stewart JH, Vajdic CM, van Leeuwen MT, Amin J, Webster AC, Chapman JR, McDonald SP, Grulich AE, McCredie MR (2009) The pattern of excess cancer in dialysis and transplantation. Nephrol Dial Transplant 24(10):3225–3231CrossRefPubMed
36.
Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, Chapman JR, Webster AC, Kaldor JM, Grulich AE (2006) Cancer incidence before and after kidney transplantation. JAMA 296(23):2823–2831CrossRefPubMed
37.
Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, Wolfe RA, Jones E, Disney AP, Briggs D, McCredie M, Boyle P (1999) Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 354(9173):93–99CrossRefPubMed
38.
Lee HH, Choi KH, Yang SC, Han WK (2012) Renal cell carcinoma in kidney transplant recipients and dialysis patients. Korean J Urol 53(4):229–233CrossRefPubMedPubMedCentral
39.
Goh A, Vathsala A (2011) Native renal cysts and dialysis duration are risk factors for renal cell carcinoma in renal transplant recipients. Am J Transplant 11(1):86–92CrossRefPubMed
40.
Demir T, Ozel L, Gökçe AM, Ata P, Kara M, Eriş C, Özdemir E, Titiz MI (2015) Cancer screening of renal transplant patients undergoing long-term immunosuppressive therapy. Transplant Proc 47(5):1413–1417CrossRefPubMed
41.
Hoshida Y, Tsukuma H, Yasunaga Y, Xu N, Fujita MQ, Satoh T, Ichikawa Y, Kurihara K, Imanishi M, Matsuno T, Aozasa K (1997) Cancer risk after renal transplantation in Japan. Int J Cancer 71(4):517–520CrossRefPubMed
42.
Lien YH, Hunt KR, Siskind MS, Zukoski C (1993) Association of cyclosporin A with acquired cystic kidney disease of the native kidneys in renal transplant recipients. Kidney Int 44(3):613–616CrossRefPubMed
43.
Yokoyama I, Hayashi S, Kobayashi T, Negita M, Yasutomi M, Uchida K, Takagi H (1995) Immunosuppressive drugs and their effect on experimental tumor growth. Transpl Int 8(4):251–255CrossRefPubMed
44.
Koehl GE, Wagner F, Stoeltzing O, Lang SA, Steinbauer M, Schlitt HJ, Geissler EK (2007) Mycophenolate mofetil inhibits tumor growth and angiogenesis in vitro but has variable antitumor effects in vivo, possibly related to bioavailability. Transplantation 83(5):607–614CrossRefPubMed
45.
Kaltenborn A, Schrem H (2013) Mycophenolate mofetil in liver transplantation: a review. Ann Transplant 18:685–696CrossRefPubMed
46.
O'Neill JO, Edwards LB, Taylor DO (2006) Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 25(10):1186–1191CrossRefPubMed
47.
Penn I (2000) Post-transplant malignancy: the role of immunosuppression. Drug Saf 23:101–113CrossRefPubMed
48.
Buell JF, Gross TG, Woodle ES (2005) Malignancy after transplantation. Transplantation 80(2 Suppl):S254–S264CrossRefPubMed
49.
Alberú J, Pascoe MD, Campistol JM, Schena FP, Rial Mdel C, Polinsky M, Neylan JF, Korth-Bradley J, Goldberg-Alberts R, Maller ES, Sirolimus CONVERT Trial Study Group (2011) Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation 92(3):303–310CrossRefPubMed
50.
Mathew T, Kreis H, Friend P (2004) Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transpl 18(4):446–449CrossRef
Metadaten
Titel
Renal cell cancer after kidney transplantation
verfasst von
Dennis Kleine-Döpke
Matthias Oelke
Anke Schwarz
Ysabell Schwager
Frank Lehner
Jürgen Klempnauer
Harald Schrem
Publikationsdatum
12.07.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Langenbeck's Archives of Surgery / Ausgabe 5/2018
Print ISSN: 1435-2443
Elektronische ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-018-1694-x

Weitere Artikel der Ausgabe 5/2018

Langenbeck's Archives of Surgery 5/2018 Zur Ausgabe

ORIGINAL ARTICLE

Is systematic nasogastric decompression after pancreaticoduodenectomy really necessary?

ORIGINAL ARTICLE

Comparison of perioperative and oncological outcome of thoracoscopic esophagectomy in left decubitus position and in prone position for esophageal cancer

ORIGINAL ARTICLE

Perioperative outcomes of laparoscopic pancreaticoduodenectomy for benign and borderline malignant periampullary disease compared to open pancreaticoduodenectomy

ORIGINAL ARTICLE

Ampullary neuroendocrine neoplasms: surgical experience of a rare and challenging entity

ORIGINAL ARTICLE

Risk factors associated with intrathyroid extension of thyroid microcarcinomas

How-I-Do-It Article

Segment 5 parenchymal sparing in extended left hepatectomy with respect to venous outflow—is it a feasible procedure?

Neu im Fachgebiet Chirurgie

10.04.2024 | Postoperative Schmerztherapie | Nachrichten

Chronische Schmerzen nach Op. oft mit neuropathischer Komponente

10.04.2024 | Narbenhernie | Nachrichten

Deutlich weniger Narbenhernien mit der Small-Bites-Technik

09.04.2024 | Appendektomie | Nachrichten

Appendektomie: Vorsicht bei systemischen Glukokortikoiden!

08.04.2024 | Andrologie | Nachrichten

Wie toxische Männlichkeit der Gesundheit von Männern schadet
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom CME-Kurs
CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur CME-Kurs
CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis CME-Kurs
CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.